- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Moderate to severe hidradenitis suppurativa
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Adalimumab – November 2019
Adalimumab: Injection 80 mg in 0.8 mL pre-filled pen, Injection 80 mg in 0.8 mL pre-filled syringe; Humira®
Last updated
6 March 2020